Holen Sie sich die Stockscreener-App
2.25
5.06%
-0.12
Handel nachbörslich:
2.25
Schlusskurs vom Vortag:
$2.37
Offen:
$2.34
24-Stunden-Volumen:
3.24M
Relative Volume:
1.20
Marktkapitalisierung:
$323.96M
Einnahmen:
$288.95M
Nettoeinkommen (Verlust:
$-119.03M
KGV:
-2.4986
EPS:
-0.9005
Netto-Cashflow:
$60.67M
1W Leistung:
+1.35%
1M Leistung:
+8.70%
6M Leistung:
-60.32%
1J Leistung:
-74.69%
1-Tages-Spanne:
$2.22
$2.35
1-Wochen-Bereich:
$2.195
$2.41
52-Wochen-Spanne:
$1.665
$10.03
Maravai Lifesciences Holdings Inc Stock (MRVI) Company Profile
Firmenname
Maravai Lifesciences Holdings Inc
Sektor
Branche
Telefon
(858) 546-0004
Adresse
10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO
Vergleichen Sie MRVI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRVI
Maravai Lifesciences Holdings Inc
|
2.25 | 319.63M | 288.95M | -119.03M | 60.67M | -0.9005 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Maravai Lifesciences Holdings Inc Stock (MRVI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-12-19 | Eingeleitet | Guggenheim | Neutral |
| 2024-12-05 | Herabstufung | Goldman | Neutral → Sell |
| 2024-11-14 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-08 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-08-13 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-04-10 | Eingeleitet | Craig Hallum | Buy |
| 2023-12-12 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-08-08 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-05-23 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-05-09 | Herabstufung | Goldman | Buy → Neutral |
| 2023-01-05 | Herabstufung | UBS | Buy → Neutral |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-11-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-12-16 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2020-12-15 | Eingeleitet | BofA Securities | Buy |
| 2020-12-15 | Eingeleitet | Credit Suisse | Outperform |
| 2020-12-15 | Eingeleitet | Goldman | Buy |
| 2020-12-15 | Eingeleitet | Jefferies | Buy |
| 2020-12-15 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-12-15 | Eingeleitet | Stifel | Buy |
| 2020-12-15 | Eingeleitet | William Blair | Outperform |
| 2020-12-14 | Eingeleitet | UBS | Buy |
Alle ansehen
Maravai Lifesciences Holdings Inc Aktie (MRVI) Neueste Nachrichten
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Stock Holdings Cut by Bank of America Corp DE - Defense World
ProShare Advisors LLC Raises Stock Holdings in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) - Defense World
Maravai LifeSciences Announces Shareholder Meeting Results - Investing.com Australia
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Maravai LifeSciences Holdings, Inc. (MRVI) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Maravai LifeSciences Sees Unusually Large Options Volume (NASDAQ:MRVI) - Defense World
Maravai Lifesciences Holds Annual Shareholders Meeting - TipRanks
Maravai LifeSciences Announces Shareholder Meeting Results By Investing.com - Investing.com Nigeria
BNP Paribas Financial Markets Purchases Shares of 66,443 Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) - Defense World
Bronstein, Gewirtz & Grossman, LLC Encourages Maravai LifeSciences Holdings, Inc. (MRVI) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
CORRECTION -- Maravai LifeSciences Releases 2024 Sustainability Report | MRVI Stock News - GuruFocus
Maravai LifeSciences Releases 2024 Sustainability Report Highlighting Product Innovation, Governance Enhancements, and Commitment to Sustainable Growth - Nasdaq
CORRECTIONMaravai LifeSciences Releases 2024 Sustainability Report - The Manila Times
CORRECTION – Maravai LifeSciences Releases 2024 Sustainability Report - GlobeNewswire
Maravai Sustainability Report: 10x Manufacturing Expansion Plus Major Green Energy Milestones - Stock Titan
Maravai LifeSciences Releases 2024 Sustainability Report - GlobeNewswire
Maravai LifeSciences Sustainability Report: 49 New Products and 10X GMP Manufacturing Expansion Drive Growth - Stock Titan
Northern Trust Corp Buys 53,474 Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) - Defense World
Revolutionary mRNA Synthesis Kit Achieves 2X Yield, 85% Lower dsRNA: TriLink's Game-Changing Launch - Stock Titan
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Consensus Recommendation of “Hold” by Brokerages - Defense World
Maravai LifeSciences Q1 2025 Earnings Call: Growth Amid Challenges - TipRanks
Price T Rowe Associates Inc. MD Acquires 7,946 Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) - Defense World
Robert W. Baird Has Lowered Expectations for Maravai LifeSciences (NASDAQ:MRVI) Stock Price - Defense World
Stock Traders Buy Large Volume of Put Options on Maravai LifeSciences (NASDAQ:MRVI) - Defense World
TriLink BioTechnologies® and the International Vaccine Institute Sign a Memorandum of Understanding to Support the Development of mRNA-based Vaccines - marketscreener.com
Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q1 Loss, Tops Revenue Estimates - MSN
RBC Capital Sticks to Their Buy Rating for Maravai Lifesciences Holdings (MRVI) - The Globe and Mail
Major mRNA Vaccine Breakthrough: TriLink and IVI Join Forces to Transform Global Vaccine Access - Stock Titan
Maravai (MRVI) Offers 2025 Revenue Outlook Excluding Key Factors - GuruFocus
MRVI: Analyst Firm Lowers Price Target for Maravai LifeSciences - GuruFocus
These Analysts Slash Their Forecasts On Maravai LifeSciences Following Q1 Results - Benzinga
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Maravai LifeSciences Holdings, Inc. (MRVI) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Maravai LifeSciences (MRVI) Exceeds Q1 Revenue Expectations | MR - GuruFocus
Maravai (MRVI) Offers 2025 Revenue Outlook Excluding Key Factors | MRVI Stock News - GuruFocus
Maravai Lifesciences (MRVI) Price Target Reduced by Baird Analys - GuruFocus
Assessing Maravai LifeSciences: Insights From 5 Financial Analysts - Benzinga
Maravai LifeSciences (MRVI) Target Price Lowered by Baird | MRVI Stock News - GuruFocus
MRVI: Analyst Reduces Price Target but Maintains Buy Rating on M - GuruFocus
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Q1 2025 Earnings Call Transcript - Insider Monkey
Maravai Lifesciences (MRVI) Price Target Reduced by Baird Analyst | MRVI Stock News - GuruFocus
Maravai LifeSciences Holdings Inc (MRVI) Q1 2025 Earnings Call Highlights: Navigating Growth ... - Yahoo Finance
Maravai LifeSciences Holdings Inc (MRVI) Q1 2025 Earnings Call H - GuruFocus
Maravai LifeSciences Holdings, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:MRVI) - Seeking Alpha
Earnings call transcript: Maravai Lifesciences Q1 2025 sees revenue beat, stock up - Investing.com
Maravai LifeSciences Q1 Adjusted Loss Widens, Revenue Falls - marketscreener.com
Maravai LifeSciences Q1 2025 Earnings: Revenue Beats Estimates a - GuruFocus
Maravai LifeSciences (MRVI) Exceeds Q1 Revenue Expectations | MRVI Stock News - GuruFocus
Maravai Lifesciences Reports First Quarter 2025 Financial Results | MRVI Stock News - GuruFocus
Maravai Lifesciences Reports First Quarter 2025 Financial Results - The Manila Times
Dimensional Fund Advisors LP Grows Position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) - Defense World
Class Action Filed Against Maravai LifeSciences Holdings, Inc. (MRVI)May 5, 2025 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire
Maravai LifeSciences (MRVI) Expected to Announce Earnings on Monday - Defense World
Finanzdaten der Maravai Lifesciences Holdings Inc-Aktie (MRVI)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.89%
3.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):